ADAR (9F2) Monoclonal Antibody

$Paraformaldehyde-fixed and paraffin-embedded Human Colon Cancer tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Colon Cancer tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$IF(ICC) staining with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100 in Hela cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Lane 1: SiHa Cells; Probed with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: SiHa Cells; Probed with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:500 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Lung Cancer tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Pancreas tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Pancreas tissue incubated with ADAR (9F2) Monoclonal Antibody (bsm-54222R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human

Overview
Catalog #	bsm-54222R
Product Name	ADAR (9F2) Monoclonal Antibody
Applications	WB, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein within human ADAR1 aa 100-300
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at 4C for up to 2 weeks. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	103
Swiss Prot	P55265
Subcellular location	Cytoplasm, Nucleus
Synonyms	Double-stranded RNA-specific adenosine deaminase; 136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; K88DSRBP; DRADA; p136; IFI-4; ADAR; ADAR1; DSRAD; G1P1; IFI4.
Background	Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200